First-line immune checkpoint inhibitors plus chemotherapy for advanced triple-negative breast cancer: A network meta-analysis and cost-effectiveness analysis

Background There are no head-to-head randomized trials comparing first-line immune checkpoint inhibitor (ICI) regimens for advanced triple-negative breast cancer (TNBC). We evaluated the comparative evidence and model-based economic outcomes of three ICI-containing regimens from the Chinese healthcare system perspective. Methods We systematically searched bibliographic databases, ClinicalTrials.gov, and oncology conference proceedings through September 1, 2026. A fixed-effect network meta-analysis (NMA) synthesized progression-free survival and overall survival hazard ratios from eligible phase III randomized trials. A decision tree combined with a three-state partitioned survival model estimated costs and quality-adjusted life-years (QALYs) over 10 years. Pembrolizumab plus chemotherapy was the primary absolute-risk survival anchor; alternative trial-specific anchors were assessed as structural scenarios. Results Three randomized trials (IMpassion130, KEYNOTE-355, and TORCHLIGHT), involving 2,280 patients, were included. Indirect comparisons did not show statistically significant differences among ICI regimens in progression-free or overall survival; the small, loop-free network limited certainty. In the base-case economic model, toripalimab plus chemotherapy had the lowest modeled cost (US$40,972.13) and highest QALYs (2.27), compared with atezolizumab plus chemotherapy (US$115,286.53; 1.82 QALYs) and pembrolizumab plus chemotherapy (US$124,952.00; 1.90 QALYs). The economic ordering was maintained across alternative survival-anchor scenarios, although absolute QALYs differed. Conclusions Under the specified Chinese health-system costs and model assumptions, toripalimab plus chemotherapy was the economically preferred strategy. This finding does not establish clinical superiority; between-trial differences and uncertainty in long-term survival extrapolation limit its interpretation and generalizability.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11311435/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

First-line immune checkpoint inhibitors plus chemotherapy for advanced triple-negative breast cancer: A network meta-analysis and cost-effectiveness analysis

Yize Jia, Shan Zhao, Shuo Yang, Shuo Kang
4 links
Research Square
Cancer Immunotherapy and Biomarkers
preprint

First-line immune checkpoint inhibitors plus chemotherapy for advanced triple-negative breast cancer: A network meta-analysis and cost-effectiveness analysis

Yize Jia, Shan Zhao, Shuo Yang, Shuo Kang
preprint en

Abstract

Background There are no head-to-head randomized trials comparing first-line immune checkpoint inhibitor (ICI) regimens for advanced triple-negative breast cancer (TNBC). We evaluated the comparative evidence and model-based economic outcomes of three ICI-containing regimens from the Chinese healthcare system perspective. Methods We systematically searched bibliographic databases, ClinicalTrials.gov, and oncology conference proceedings through September 1, 2026. A fixed-effect network meta-analysis (NMA) synthesized progression-free survival and overall survival hazard ratios from eligible phase III randomized trials. A decision tree combined with a three-state partitioned survival model estimated costs and quality-adjusted life-years (QALYs) over 10 years. Pembrolizumab plus chemotherapy was the primary absolute-risk survival anchor; alternative trial-specific anchors were assessed as structural scenarios. Results Three randomized trials (IMpassion130, KEYNOTE-355, and TORCHLIGHT), involving 2,280 patients, were included. Indirect comparisons did not show statistically significant differences among ICI regimens in progression-free or overall survival; the small, loop-free network limited certainty. In the base-case economic model, toripalimab plus chemotherapy had the lowest modeled cost (US$40,972.13) and highest QALYs (2.27), compared with atezolizumab plus chemotherapy (US$115,286.53; 1.82 QALYs) and pembrolizumab plus chemotherapy (US$124,952.00; 1.90 QALYs). The economic ordering was maintained across alternative survival-anchor scenarios, although absolute QALYs differed. Conclusions Under the specified Chinese health-system costs and model assumptions, toripalimab plus chemotherapy was the economically preferred strategy. This finding does not establish clinical superiority; between-trial differences and uncertainty in long-term survival extrapolation limit its interpretation and generalizability.

Research Square
Hebei Medical University (CN), Second Hospital of Hebei Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon